ERNA
NASDAQ · Biotechnology
Ernexa Therapeutics Inc
$6.62
-0.41 (-5.83%)
Financial Highlights (FY 2026)
Revenue
18.39M
Net Income
-1,407,587,770
Gross Margin
83.5%
Profit Margin
-7,652.8%
Rev Growth
-69.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 83.5% | 83.5% | 35.7% | 35.7% |
| Operating Margin | -6,548.8% | -5,893.9% | -3.8% | -3.6% |
| Profit Margin | -7,652.8% | -7,270.1% | -3.2% | -3.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 18.39M | 59.60M | 759.7K | 723.6K |
| Gross Profit | 15.36M | 49.77M | 270.9K | 258.0K |
| Operating Income | -1,204,534,274 | -3,512,899,697 | -28,606 | -26,110 |
| Net Income | -1,407,587,770 | -4,105,084,228 | -24,634 | -22,962 |
| Gross Margin | 83.5% | 83.5% | 35.7% | 35.7% |
| Operating Margin | -6,548.8% | -5,893.9% | -3.8% | -3.6% |
| Profit Margin | -7,652.8% | -7,270.1% | -3.2% | -3.2% |
| Rev Growth | -69.1% | -69.1% | +6.1% | +6.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 1.20M | 1.05M |
| Total Equity | — | — | 1.80M | 2.01M |
| D/E Ratio | — | — | 0.67 | 0.52 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -1,182,760,510 | -3,641,032,030 | -38,889 | -37,851 |
| Free Cash Flow | — | — | -29,815 | -29,431 |